

Checklist for Ocrevus (ocrelizumab) Referral

Patien	t Name: Date: Date:			
Referri	ing Physician: NPI:			
Office	Contact/Title/Email:			
Office	Address:			
Office	Phone: Office Fax:			
Best co	ontact number for physician in case of reaction:			
Please	return completed checklist and checklist items to initiate referral. Use this form as fax cover sheet.			
	Patient demographic information			
	☐ Insurance information and copy of insurance card/s (front and back). *Include primary and secondary insurance			
	☐ Supporting clinical notes and office visits. Two notes preferred.			
	 Note should include any therapies tried/failed, and must include discussion about Ocrevus Medication list and allergies Last Ocrevus infusion note, if available 			
☐ Supporting lab reports/orders for Ocrevus treatment				
	 Baseline: CBC w diff, CMP, serum immunoglobulins, Hepatitis B screening, tuberculosis screening, and brain MRI within 1 year 			
	o For continued therapy: CBC w diff and CMP prior to each infusion			
	o Ensure all vaccinations are up to date prior to treatment. Live vaccines should be given at least 4 weeks			
	prior to treatment, and non-live vaccines should be given at least 2 weeks prior to treatment.			
	Ocrevus Prescribing Order (see attached)			
	We will obtain prior authorization and schedule your patient as soon as possible –			
	Fax all information to our Infusion Coordinator: 508-698-8671			

Visit our website: www.InfusionCenterNE.com
Email: InfusionCenter@myneurodr.com

Call with any questions: 781-551-5812 ext. 112



Prescribing Order: Ocrevus (ocrelizumab)

Date of Order: Patient Name:		☐ New Start ☐ Maintenance Date of last infusion:		
		DOB:	M/F:	
Diagnosis	(include ICD-10 code/s):			
□ NKDA	Allergies:			
Patient We	eight:			
Premedica	ation:			
	minophen 1000mg PO	Diphenhydramine 25m	g IV	
☐ Lorata	dine 10mg or Cetirizine 10mg PO	☐ Solu-medrol 125mg IV	in 50ml over 15min	
Dipher	nhydramine 25mg PO	☐ Other:	-	
Lab Orders				
☐ CBC w	/diff, CMP every weeks	☐ Other:		
Ocrevus M	Medication Order: **Use 0.2 micron filter f	or administration**		
OCICVUS IV	☐ Ocrevus 300mg/250ml NS IV on Day		l/hr and increase by 30ml/hr	
	every 30min to a maximum rate of 1	.80ml/hr.		
	☐ Ocrevus 600mg/500ml NS IV once	every 6 months. Begin infusion at 40	ml/hr then increase rate by	
	40ml/hr every 30 minutes to a maxi	mum rate of 200ml/hr until completion	on.	
	☐ Shorter Infusion Time: Ocrevus 600	mg/500ml NS IV once every 6 months	s. Begin infusion at 100ml/hr	
	for the first 15 min, increase to 200n	nl/hr for the next 15 min, increase to 2	250ml/hr for the next 30 min,	
	then increase to 300ml/hr for the re	maining 60 min.		
✓	Post infusion observation: Required for 1	hour after Ocrevus completion		
	☐ NS 100ml/hr x 1 hour			
Administra	ation:			
✓	Vital Signs: Pre-treatment then every 30	minutes during infusion		
✓	✓ Do not administer if patient has signs or symptoms of active infection			
✓	In case of infusion reaction, STOP infusio	n and follow ICNE infusion reaction pro	otocol. Notify physician.	
Ordering F	Provider Name	NPI		
Signature		Date		